EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition

Kirsten Brooksbank, Sarah A Martin

The International Journal of Biochemistry & Cell Biology · 2023-11 · 164 · 106477

DOI: 10.1016/j.biocel.2023.106477 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2023-11. Verfasst von Kirsten Brooksbank und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cancer Cell & Molecular Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Cancer Research UK, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DNA mismatch repair pathway is involved in the identification, excision, and repair of base-base mismatches and indel loops in the genome. Mismatch repair deficiency occurs in approximately 20% of all cancers and results in a type of DNA damage called microsatellite instability. In 2017, the immune checkpoint inhibitor, Pembrolizumab, an anti-PD-1 therapy, was approved for use in all unresectable or metastatic tumours that were mismatch repair deficient or had high microsatellite instability regardless of tissue origin. This landmark approval was the first time a drug had been approved in a site agnostic way, but accumulating data has revealed that up to 50% of mismatch repair deficient tumours are refractory to treatment and there is a huge amount of variability in the therapeutic benefit amongst responders. Several mechanisms of resistance to immune checkpoint blockade for mismatch repair deficient cancers have been identified but our understanding of what is driving resistance in a proportion of patients remains lacking. In this review article, we discuss the emerging mechanisms of resistance which may enable optimal stratification of patients for treatment with immune checkpoint inhibitors in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsImmune Checkpoint InhibitorsDNA Mismatch RepairBiomarkers, TumorMicrosatellite InstabilityNeoplastic Syndromes, HereditaryHumansBrain Neoplasms

Stichwörter der Autor:innen

DNA Mismatch repair pathwayDrug resistanceImmune checkpoint blockade

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Centre for Cancer Cell & Molecular Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
  • Centre for Cancer Cell & Molecular Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Electronic address: sarah.martin@qmul.ac.uk.

Förderung

  • Wellcome Trust
  • Cancer Research UK
  • Medical Research Council

Zitieren

APA

Brooksbank, K., & Martin, S. A. (2023). DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition. The International Journal of Biochemistry & Cell Biology, 164, 106477. https://doi.org/10.1016/j.biocel.2023.106477

Vancouver

Brooksbank K, Martin SA. DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition. The International Journal of Biochemistry & Cell Biology. 2023;164:106477. doi:10.1016/j.biocel.2023.106477

BibTeX
@article{Brooksbank2023,
  author = {Brooksbank, Kirsten and Martin, Sarah A},
  title = {DNA mismatch repair deficient cancer – Emerging biomarkers of resistance to immune checkpoint inhibition},
  journal = {The International Journal of Biochemistry & Cell Biology},
  year = {2023},
  volume = {164},
  pages = {106477},
  doi = {10.1016/j.biocel.2023.106477}
}
Kostenlos starten →